Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study

British Journal of Cancer

Volumn 116, Issue 12, 2017, Pages 1652-1659

  Gray, Ronan T ^a   Loughrey, Maurice B ^a,b   Bankhead, Peter ^a   Cardwell, Chris R ^a   McQuaid, Stephen ^a   O'Neill, Roisin F ^a   Arthur, Kenneth ^a   Bingham, Victoria ^a   McGready, Claire ^a   Gavin, Anna T ^a   James, Jacqueline A ^a,b   Hamilton, Peter W ^a   Salto Tellez, Manuel ^a,b   Murray, Liam J ^a   Coleman, Helen G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

colonic neoplasms; HMGCR protein; hydroxymethylglutaryl CoA reductase inhibitors; KRAS; survival; tumour suppressor protein p53

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PROTEIN P53; TUMOR MARKER; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLON ADENOCARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FEMALE; GENE MUTATION; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ONCOGENE K RAS; OVERALL SURVIVAL; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; VERY ELDERLY; WILD TYPE; CHEMISTRY; COLON TUMOR; GENETICS; METABOLISM; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC NETWORKS AND PATHWAYS; MEVALONIC ACID; MIDDLE AGED; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85020413934     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.139     Document Type: Article

References (35)

1. Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP (2014) Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol 15: e461-e468.
2. Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59: 1572-1585.
3. Bengtsson E, Nerjovaj P, Wangefjord S, Nodin B, Eberhard J, Uhlén M, Borgquist S, Jirström K, Uhlen M, Borgquist S, Jirstrom K (2014) HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome. Diagn Pathol 9: 78.
4. Bjarnadottir O, Romero Q, Bendahl P-O, Jirström K, Rydén L, Loman N, Uhlén M, Johannesson H, Rose C, Grabau D, Borgquist S (2013) Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138: 499-508.
5. Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K (2008) Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res 10: R79.
6. Boyle DP, McArt DG, Irwin G, Wilhelm-Benartzi CS, Lioe TF, Sebastian E, McQuaid S, Hamilton PW, James JA, Mullan PB, Catherwood MA, Harkin DP, Salto-Tellez M (2014) The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology 65: 340-352.
7. Brennan DJ, Brändstedt J, Rexhepaj E, Foley M, Pontén F, Uhlén M, Gallagher WM, O'Connor DP, O'Herlihy C, Jirstrom K (2010) Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer 10: 125.
8. Brennan DJ, Laursen H, O'Connor DP, Borgquist S, Uhlen M, Gallagher WM, Pontén F, Millikan RC, Rydén L, Jirström K (2011) Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. Breast Cancer Res 13: R12.
9. Cardwell CR, Hicks BM, Hughes C, Murray LJ (2014a) Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol 32: 3177-3183.
10. Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, Murray LJ (2014b) Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology 146: 700-708.
11. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon S-H, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Børresen-Dale A-L, Levine AJ, Bargonetti J, Prives C (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: 244-258.
12. Fumagalli D, Gavin PG, Taniyama Y, Kim S-I, Choi H-J, Paik S, Pogue-Geile KL (2010) A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 10: 101.
13. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343: 425-430.
14. Gray RT, Coleman HG, Hughes C, Murray LJ, Cardwell CR (2016) Statin use and survival in colorectal cancer: results from a population-based cohort study and an updated systematic review and meta-analysis. Cancer Epidemiol 45: 71-81.
15. Gustbée E, Tryggvadottir H, Markkula A, Simonsson M, Nodin B, Jirström K, Rose C, Ingvar C, Borgquist S, Jernström H (2015) Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clin Pathol 15: 8.
16. Hoffmeister M, Jansen L, Rudolph A, Toth C, Kloor M, Roth W, Blaker H, Chang-Claude J, Brenner H (2015) Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer Inst 107: djv045.
17. Kaye PV, Haider SA, James PD, Soomro I, Catton J, Parsons SL, Ragunath K, Ilyas M (2010) Novel staining pattern of p53 in Barrett's dysplasia-the absent pattern. Histopathology 57: 933-935.
18. Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 11: 1.
19. Kim B, Park SJ, Hong SP, Cheon JH, Kim WH, Kim TI (2015) The effect of prediagnostic aspirin use on the prognosis of stage III colorectal cancer. Int J Clin Exp Med 8: 13435-13445.
20. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG (2007) Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6: 541-555.
21. Krens LL, Simkens LHJ, Baas JM, Koomen ER, Gelderblom H, Punt CJA, Guchelaar H-JJ (2014) Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. PLoS One 9: e112201.
22. Köbel M, Reuss A, du Bois A, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB (2010) The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 222: 191-198.
23. Lee JE, Baba Y, Ng K, Giovannucci E, Fuchs CS, Ogino S, Chan AT (2011) Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res 4: 1808-1815.
24. Lim SH, Kim TW, Hong YS, Han S-W, Lee K-H, Kang HJ, Hwang IG, Lee JY, Kim HS, Kim ST, Lee J, Park JO, Park SH, Park YS, Lim HY, Jung S-H, Kang WK (2015) A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. Br J Cancer 113: 1421-1426.
25. Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340: b5087.
26. Mace AG, Gantt GA, Skacel M, Pai R, Hammel JP, Kalady MF (2013) Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum 56: 1217-1227.
27. McCarty KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigler HF, McCarty KS (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46: 4244s-4248s.
28. McCluggage WG, Soslow RA, Gilks CB (2011) Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology 59: 786-788.
29. Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson III AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS (2011) Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 103: 1540-1551.
30. Ogino S, Chan AT, Fuchs CS, Giovannucci E (2011) Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60: 397-411.
31. Ogino S, Fuchs CS, Giovannucci E (2012) How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 12: 621-628.
32. Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A (2016) PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies. Clin Oncol 28: 317-326.
33. Thurnher M, Nussbaumer O, Gruenbacher G (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 18: 3524-3531.
34. Zanders MMJ, van Herk-Sukel MPP, Vissers PAJ, Herings RMC, Haak HR, van de Poll-Franse LV (2015) Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Br J Cancer 113: 403-410.
35. Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES-C (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16: 79-84.